GSK (LON:GSK) Price Target Raised to GBX 2,200

GSK (LON:GSK) had its target price boosted by Berenberg Bank from GBX 2,000 to GBX 2,200 in a research note published on Tuesday morning,Digital Look reports. They currently have a hold rating on the stock.

A number of other equities research analysts have also weighed in on the company. Royal Bank Of Canada reiterated a “sector perform” rating and issued a GBX 1,975 price objective on shares of GSK in a research report on Tuesday, September 8th. Jefferies Financial Group restated a “buy” rating and set a GBX 2,500 target price on shares of GSK in a report on Wednesday, July 29th. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating and issued a GBX 2,000 price target on shares of GSK in a research note on Wednesday, September 2nd. Two equities research analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of GBX 2,064.38.

GSK Stock Performance

Shares of LON:GSK opened at GBX 1,900 on Tuesday. The company has a current ratio of 0.82, a quick ratio of 0.73 and a debt-to-equity ratio of 103.36. The company has a 50-day moving average price of GBX 1,892.75 and a 200-day moving average price of GBX 1,957.30. The company has a market cap of £76.13 billion, a price-to-earnings ratio of 16.13, a price-to-earnings-growth ratio of 1.24 and a beta of 0.29. GSK has a 12 month low of GBX 1,455 and a 12 month high of GBX 2,282.

GSK (LON:GSK) last announced its quarterly earnings results on Tuesday, July 28th. The company reported GBX 10.80 earnings per share (EPS) for the quarter. GSK had a return on equity of 28.35% and a net margin of 14.52%. As a group, equities analysts anticipate that GSK will post 175.980975 EPS for the current year.

Insider Transactions at GSK

In related news, insider Vishal Sikka acquired 1,266 shares of the stock in a transaction on Monday, June 22nd. The stock was acquired at an average cost of GBX 5,069 per share, for a total transaction of £64,173.54. Also, insider Jeannie Lee acquired 802 shares of the business’s stock in a transaction on Monday, June 22nd. The shares were purchased at an average cost of GBX 5,069 per share, for a total transaction of £40,653.38. Over the last three months, insiders purchased 2,075 shares of company stock valued at $10,495,313. 0.20% of the stock is owned by insiders.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.